Abrepa Pharmaceuticals

Abrepa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative topical therapies for dermatological and infectious diseases. The company's lead product candidate, AB-101, is a proprietary topical solution currently undergoing Phase 2 clinical trials for the treatment of molluscum contagiosum and common warts (verruca vulgaris). Abrepa aims to provide patients with effective, non-invasive, and painless treatment options for viral skin conditions that currently have limited therapeutic choices. Headquartered in New Jersey, the company is led by an experienced management team with a track record in global drug development and commercialization. Abrepa's approach leverages botanical-derived compounds to address significant unmet needs in the dermatology market.